Sugi Predict

Sugi Predict / Compounds / SCHEMBL650818

SCHEMBL650818

SCHEMBL650818

CCOC(=O)c1cnc(S(C)(=O)=O)nc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.60
▸ NPC1 O15118 2/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ TP53 P04637 1/20 0.60
▸ MAPT P10636 1/20 0.60
▸ XBP1 P17861 1/20 0.60
▸ MAPK1 P28482 1/20 0.60
▸ NPSR1 Q6W5P4 1/20 0.60
▸ HSD17B10 Q99714 1/20 0.60
▸ TLR9 Q9NR96 1/20 0.60
▸ THRB P10828 1/20 0.52
▸ HPGD P15428 3/20 0.51
▸ RECQL P46063 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ CA1 P00915 3/20 0.49
▸ CA2 P00918 3/20 0.49
▸ CA12 O43570 2/20 0.49
▸ CA7 P43166 2/20 0.49
▸ CA9 Q16790 2/20 0.49
▸ CA14 Q9ULX7 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27372061 0.86 HTT (0.49) HTTNPC1ALDH1A1TP53MAPT
SCHEMBL18356307 0.83 HTT (0.47) HTTNPC1ALDH1A1TP53MAPT
SCHEMBL20588293 0.81 MAPT (0.55) HTTNPC1ALDH1A1TP53MAPT
SCHEMBL2970976 0.80 MAPK1 (0.50) HTTNPC1ALDH1A1TP53MAPT
SCHEMBL2642000 0.80 CYP2C9 (0.53) HTTNPC1ALDH1A1MAPTMAPK1
SCHEMBL14799056 0.79 HPGD (0.59) HTTNPC1ALDH1A1TP53MAPT
SCHEMBL4763594 0.79 MAPT (0.63) HTTNPC1ALDH1A1TP53MAPT
SCHEMBL6880667 0.78 CA12 (0.55) HTTNPC1ALDH1A1HPGDCA1
SCHEMBL5364037 0.77 LMNA (0.56) NPC1ALDH1A1TP53MAPTHSD17B10
SCHEMBL829286 0.77 CYP2C9 (0.50) HTTNPC1ALDH1A1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398130-B2 Acid addition salts of piperazine derivatives ASCENEURON SA (CH) 2025-08-26 — — US disclosed
US-12187741-B2 Glycosidase inhibitors ASCENEURON SA (CH) 2025-01-07 — — US disclosed
CN-114539267-B Evodiamine derivative and application thereof 中国人民解放军海军军医大学 2023-04-28 — — CN disclosed
US-20230120169-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES ASCENEURON SA (CH) 2023-04-20 — — US disclosed
US-11591327-B2 Acid addition salts of piperazine derivatives ASCENEURON SA (CH) 2023-02-28 — — US disclosed
CN-109071526-B Acid addition salts of piperazine derivatives 阿森纽荣股份公司 2023-02-28 — — CN disclosed
US-20220411440-A1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2022-12-29 — — US disclosed
CN-115304585-A Preparation method of avanafil 江苏恒沛药物科技有限公司 2022-11-08 — — CN disclosed
CN-108884081-B Process for separating enantiomers of piperazine derivatives 阿森纽荣股份公司 2022-11-01 — — CN disclosed
CN-114539267-A Evodiamine derivative and application thereof 中国人民解放军海军军医大学 2022-05-27 — — CN disclosed
CN-1642551-A Inhibitors of histone deacetylase JANSSEN PHARMACEUTICA NV (BE) 2005-07-20 — — CN disclosed
CN-1642931-A Sulfonyl derivatives as novel histone deacetylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2005-07-20 — — CN disclosed
CN-1642912-A Sulfonylamino-derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA NV (BE) 2005-07-20 — — CN disclosed
CN-1642907-A Carbonylamino-derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA NV (BE) 2005-07-20 — — CN disclosed
CN-1642948-A Piperazinyl-, piperidinyl-and morpholinyl derivatives as novel histone deacetylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2005-07-20 — — CN disclosed
CN-1639125-A Novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA NV (BE) 2005-07-13 — — CN disclosed
US-20050107384-A1 to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC ORTHO-MCNEIL PHARMACEUTICAL INC. 2005-05-19 — — US disclosed
EP-1093367-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2003-03-05 — — EP disclosed
EP-1093367-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-04-25 — — EP disclosed
WO-1999066925-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107384-A1 to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC HDAC1, HDAC11, HDAC5 HTT 2025/4885NPC1 2429/4885ALDH1A1 1048/4885
US-20230120169-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES DNPEP, GAA, SLC30A5 HTT 2704/4885NPC1 975/4885ALDH1A1 63/4885
US-20220411440-A1 GLYCOSIDASE INHIBITORS GAA, ENGASE, GBA3 HTT 455/4885NPC1 386/4885ALDH1A1 778/4885
US-11591327-B2 Acid addition salts of piperazine derivatives DNPEP, GAA, SLC30A5 HTT 2704/4885NPC1 975/4885ALDH1A1 63/4885
US-12187741-B2 Glycosidase inhibitors GAA, ENGASE, GBA3 HTT 455/4885NPC1 386/4885ALDH1A1 778/4885
US-12398130-B2 Acid addition salts of piperazine derivatives DNPEP, GAA, SLC30A5 HTT 2704/4885NPC1 975/4885ALDH1A1 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.